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Objectives
To assess efectiveness and safety of leflunomide (LFN)
in juvenile idiopathic arthritis patients (JIA).
Methods
We performed a retrospective medical charts review in
all JIA patients who received LFN between Jan 2006 to
Mar 2011 from our outpatient Pediatric Rheumatology
Clinics. We collected data of: gender, age, type of JIA,
date of onset, date of diagnosis, date of first DMARD,
uveitis, reason to indiciate LFN, concomitant therapies,
reason to discontinuation, joint activity (tender and
swollen, low rang of motion count), and biological mar-
kers at baseline, 3 and 12-months follow-up.
Results
We found 32 patients had used LFN sometime. Patients
received oral 20 mg/daily LFN as compassionate therapy
after methotreate use (at conventional dosage of 10-
15mg/m2), in all cases. We present data from the first
14 patient medical charts reviewed. Female 11 and 3
Male; 7/14 olygoarticular ANA positive, 3/14 uveitis; 11/
14 maintained LFN after one year-follow up. Reason: 5
due to partial response, 5 due to adverse event, and 4
due to intolerance, to methotrexate. 7/14 received com-
bined therapy with etanercept, and 3/14 with infliximab.
10/14 (71%) received LFN for at least one year, 2/14
(14%) withdrawn LFN use due to clinical remission.
Conclusions
71% of patients who received LFN showed efficacy and
only 14% had adverse events (recovered). Most were
ANA positive oligoarticular JIA, and 2 more had uveitis.
Safety seemed acceptable either alone or with antiTNF
concomitant use.
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